Rest of the World Factor VIII Deficiency Treatment Market, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologic (Hemlibra), and Desmopressin), by Distribution Channel (Hospital Pharmacies,

Rest of the World Factor VIII Deficiency Treatment Market, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologic (Hemlibra), and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Latin America, Asia Pacific, Middle East & Russia, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hemophilia, a factor VIII deficiency is a genetic disorder that is caused by the absence of factor VIII, which is a clotting protein. Moreover, it is genetically passed down to the offspring and according to the National Hemophilia Foundation, in 2019 about 1/3 cases of factor VIII deficiency occurs due to spontaneous mutation in the gene of the parents. Rising incidences and prevalence of hemophilic disorder are expected to boost growth of the market over the forecast period which leads to product launches in the market by the key players, to fulfill the unmet need of the market. Favorable regulatory scenarios and guidelines for the product launches and treatment are another leading factors that are expected to propel growth of the market over the forecast period.
Furthermore, adoption of inorganic strategies by market players such as collaborations to develop the novel therapies for the treatment is also expected to fuel growth of the factor VIII deficiency treatment market over the forecast period. For instance, in July 2019, Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer, Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A
Market Dynamics
Factor VIII deficiency treatment market is expected to witness significant growth over the forecast period, owing to increasing number of hemophilic cases. For instance, according to the World Federation of Hemophilia 2017 statistics, in India, around 18,353 people suffered from hemophilia and 15,218 people were diagnosed with hemophilia A in 2016, out of which around 83.0% had factor VIII deficiency. Moreover, according to the World Federation of Hemophilia reports published in 2017, there were around 10,000 patients with hemophilia A in Brazil. With reference to prior data, World Federation of Hemophilia also reports that in 2017, Brazil had the third largest hemophilia patient population.
Product approvals by the regulatory authorities is expected to drive the growth of factor VIII deficiency treatment market over the forecast period. For instance, in 2019 February, the U.S. Food and Drug Administration approved the biologics license application of Novo Nordisk’s long-acting recombinant factor VIII product, N8-GP Turoctocog alfa pegol (Esperoct), for prevention and treatment of individuals with hemophilia A. Moreover, in 2016 March, the U.S. Food and Drug Administration approved Kedrion’s, Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial, for the treatment of factor VIII deficiency.
Major players are also focused on adopting inorganic growth strategies such as acquisitions, which is expected to fuel the market growth over the forecast period. For instance, in 2021, CSL Behring acquired China-based plasma-derived therapies manufacturer, Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. from Humanwell Healthcare Group Co. Ltd. The acquisition has expanded CSL’s presence in China’s domestic plasma fractionation market. It has also enabled CSL to expand their commercial footprint and contributing their expertise for benefit of patients with rare diseases in China.
Key features of the study:
This report provides in-depth analysis of the factor VIII deficiency treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the rest of the world factor VIII deficiency treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as part of this study include Baxter International, Inc., Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology upgradation, market expansion, and marketing tactics
The global factor VIII deficiency treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the factor VIII deficiency treatment market.
Detailed Segmentation:
Rest of the World Factor VIII Deficiency Treatment Market, By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Biologic (Hemlibra)
Desmopressin
Rest of the World Factor VIII Deficiency Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of the World Factor VIII Deficiency Treatment Market, By Region:
Latin America
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Biologic (Hemlibra)
Desmopressin
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Colombia
Rest of Latin America
Asia Pacific
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Biologic (Hemlibra)
Desmopressin
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Indonesia
Malaysia
Philippines
Singapore
Thailand
Rest of ASEAN Countries
Australia
South Korea
Pakistan
Rest of Asia Pacific
Middle East & Russia
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Biologic (Hemlibra)
Desmopressin
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Saudi Arabia
United Arab Emirates
Israel
Russia
Turkey
Rest of Middle East
Africa
By Product Type:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Biologic (Hemlibra)
Desmopressin
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
North Africa
Algeria
Egypt
Tunisia
Central Africa
South Africa
Company Profiles
Baxter International, Inc*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Market Strategies
Biogen, Inc.
Bayer AG
CSL Behring
Ferring B.V.
F. Hoffmann-La Roche AG
Pfizer, Inc.
Kedrion
Novo Nordisk A/S
“*” marked represents similar segmentation in other categories in the respective section.